Abstract
Purpose
Recently, more vaporization techniques are available for the treatment of benign prostate hyperplasia (BPH). However, the detection of incidental prostate cancer (Pca) is impossible in vaporization techniques because of unavailability prostate tissue for histopathological analysis. To evaluate the clinical backgrounds and the usefulness of prostate-specific antigen (PSA)-related factors in incidental Pca, we employed our BPH patients cohort treated by holmium laser enucleation of the prostate (HoLEP).
Methods
A total of 365 HoLEPs were performed by a single surgeon. The pathological results and pre- and post-HoLEP PSA, PSA density and PSA velocity were analyzed retrospectively.
Results
Incidental Pca was identified in 25 (6.8 %) of the 365 patients treated with HoLEP. There were significant differences between BPH and Pca in terms of prostate volume (55.5 vs. 47 ml, p = 0.0365), preoperative PSA (4.50 vs. 7.14 ng/ml, p = 0.0107), PSA density (0.079 vs. 0.155 ng/ml/cm3, p = 0.0005), and postoperative PSA velocity (0.04 vs. 0.22 ng/ml/year, p = 0.0033), respectively. Comparisons of Gleason score subgroups in the 25 patients with incidental Pca identified significant differences in preoperative PSA (6.06 vs. 21.6 ng/ml, p = 0.0191) and postoperative PSA velocity (0.185 vs. 1.32 ng/ml/year, p = 0.0382) between the Gleason score 3 + 3 and Gleason score >3 + 3 groups, respectively.
Conclusions
Risk factors associated with incidental Pca were smaller prostate volume, higher preoperative PSA, and higher PSA density. Postoperative PSA velocity was also significantly increased in patients with incidental Pca, especially those with higher Gleason score. These finding may be useful in incident Pca patients treated by the vaporization technique.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Zigeuner RE, Lipsky K, Riedler I et al (2003) Did the rate of incidental prostate cancer change in the era of PSA testing? A retrospective study of 1127 patients. Urology 62:451–455
Capitanio U, Scattoni V, Freschi M et al (2008) Radical prostatectomy for incidental (stage T1a–T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence. Eur Urol 54:118–125
Zhang G, Wasserman NF, Sidi AA, Reinberg Y, Reddy PK (1991) Long-term followup results after expectant management of stage A1 prostatic cancer. J Urol 146:99–102; discussion 102–103
Elzayat EA, Al-Mandil MS, Khalaf I, Elhilali MM (2009) Holmium laser ablation of the prostate versus photoselective vaporization of prostate 60 cc or less: short-term results of a prospective randomized trial. J Urol 182:133–138
Nunez R, Hurd KJ, Noble BN, Castle EP, Andrews PE, Humphreys MR (2011) Incidental prostate cancer revisited: early outcomes after holmium laser enucleation of the prostate. Int J Urol 18:543–547
Elmansy HM, Elzayat EA, Sampalis JS, Elhilali MM (2009) Prostatic-specific antigen velocity after holmium laser enucleation of the prostate: possible predictor for the assessment of treatment effect durability for benign prostatic hyperplasia and detection of malignancy. Urology 74:1105–1110
Arlen PM, Bianco F, Dahut WL et al (2008) Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time. J Urol 179:2181–2185; discussion 2185–2186
Jones JS, Follis HW, Johnson JR (2009) Probability of finding T1a and T1b (incidental) prostate cancer during TURP has decreased in the PSA era. Prostate Cancer Prostate Dis 12:57–60
Melchior S, Hadaschik B, Thuroff S, Thomas C, Gillitzer R, Thuroff J (2009) Outcome of radical prostatectomy for incidental carcinoma of the prostate. BJU Int 103:1478–1481
Naspro R, Freschi M, Salonia A et al (2004) Holmium laser enucleation versus transurethral resection of the prostate. Are histological findings comparable? J Urol 171:1203–1206
Tinmouth WW, Habib E, Kim SC et al (2005) Change in serum prostate specific antigen concentration after holmium laser enucleation of the prostate: a marker for completeness of adenoma resection? J Endourol 19:550–554
Nomura H, Seki N, Yamaguchi A, Naito S (2009) Comparison of photoselective vaporization and standard transurethral resection of the prostate on urodynamics in patients with benign prostatic hyperplasia. Int J Urol 16:657–662
Hirasawa Y, Ide H, Yasumizu Y, Hoshino K, Ito Y, Masuda T (2012) Comparison of transurethral enucleation with bipolar and transurethral resection in saline for managing benign prostatic hyperplasia. BJU Int 110:E864–E869
Eggener SE, Scardino PT, Walsh PC et al (2011) Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol 185:869–875
Acknowledgments
This work was supported by Kakenhi (Grant Nos. 25462484 and 24890160) from the Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT), Japan, and a Medical Research Promotion Grant from Takeda Science Foundation, Japan.
Conflict of interest
The authors declare they have no conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Otsubo, S., Yokomizo, A., Mochida, O. et al. Significance of prostate-specific antigen-related factors in incidental prostate cancer treated by holmium laser enucleation of the prostate. World J Urol 33, 329–333 (2015). https://doi.org/10.1007/s00345-014-1310-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00345-014-1310-9